The broad, long-term objective of this proposal is to elucidate the effects of soy foods on metastatic cancers. Metastatic cancer cells in primary tumors, or in the circulation, may establish secondary metastases at distant sites via a plethora of triggers, including dietary and environmental factors. Much work has been conducted on dietary soy in cancer prevention, but not in metastasis of established cancers. Therefore, this proposal addresses a gap in knowledge concerning the role and molecular targets of the major soy isoflavones in metastatic breast cancer. The rationale comes from data generated during the previous SC3 award. We reported that dietary administration of daidzein, or combined genistein, daidzein, and glycitein (5:4:1) in the ratio found in soy foods, increased mammary tumor growth and metastasis in a mouse model. Dietary daidzein or soy isoflavones upregulated gene expression of eukaryotic protein synthesis initiation factors eIF4E and eIF4G, as well as protein expression of pro-cancer molecules sensitive to elevated eIF4E and eIF4G levels. Subsequently, we published that equol, a metabolite of daidzein produced by intestinal bacteria, is a pivotal soy isoflavone that contributes to cancer malignancy by increasing the expression of proteins that govern metastasis. This proposal will build upon the results of the previous award by testing the hypothesis that soy isoflavones regulate cancer progression via regulation of protein synthesis initiation. Human metastatic breast cancer cell lines that represent various breast cancer types: estrogen receptor positive, triple negative, and HER2 type, will be used for the following Specific Aims.
Specific Aim 1 will delineate the effects of individual or combined soy isoflavones, genistein, daidzein, equol, and glycitein, on regulation of protein synthesis initiation and cell functions relevant to cancer progression in vitro.
This Aim wll also determine the contribution of soy-isoflavone-mediated upregulation of eIF4G and eIF4E to cancer progression by testing the effects of eIF4G or eIF4E knockdown, or rapamycin to inhibit eIF4E. Since equol increased the expression of the central transcription factor c-Myc, a role for c-Myc in upregulation of protein synthesis initiation factors in response to soy isoflavones will also be tested.
Specific Aim 2 will validate the role of the daidzein metabolite equol as the key cancer promoting component of soy isoflavones. The effect of equol on metastasis, individually or in combination with genistein and glycitein, will be determined in immunocompromised mice with mammary tumors established from metastatic human breast cancer cells. Mice will also be treated with control or small interfering RNA (siRNA) to eIF4G to investigate a role for eIF4G in equol-mediated tumor growth and metastasis. Extracted tumors and lung metastases from this Aim will also be tested for expression of pro-cancer molecules. This comprehensive experimental strategy is expected to delineate the molecular basis for potential detrimental effects of soy consumption in breast cancer patients and survivors. Therefore, the proposed research is highly relevant to the mission of the National Institute of General Medical Sciences.
Soy is the third predominant cash crop in the US, and soy-based diets are often recommended for cancer patients and survivors. Most studies on dietary soy have focused on cancer prevention and not the effect of soy consumption for cancer patients or those at risk for metastatic cancer. Investigation of the effect of soy foods on cancer metastasis is critical since metastasis is often the cause of death from epithelial cancers such as breast cancer. The proposed study will delineate a cancer promoting role for soy isoflavones in metastatic cancer, and delineate new mechanisms of action for individual and combined soy isoflavones in the ratio and levels found in soy foods. This research is relevant to public health because it can impact dietary and therapeutic decisions for patients diagnosed with cancer as well as cancer survivors.
|Rivera-Robles, Michael John; Medina-Velázquez, Julia; Asencio-Torres, Gabriela M et al. (2018) Targeting Cdc42 with the anticancer compound MBQ-167 inhibits cell polarity and growth in the budding yeast S. cerevisiae. Small GTPases :1-11|
|Maldonado, María Del Mar; Dharmawardhane, Suranganie (2018) Targeting Rac and Cdc42 GTPases in Cancer. Cancer Res 78:3101-3111|
|Rivera Rivera, Amilcar; Castillo-Pichardo, Linette; Gerena, Yamil et al. (2016) Anti-Breast Cancer Potential of Quercetin via the Akt/AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Cascade. PLoS One 11:e0157251|
|de la Parra, Columba; Castillo-Pichardo, Linette; Cruz-Collazo, Ailed et al. (2016) Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein. Nutr Cancer 68:154-64|
|de la Parra, Columba; Borrero-Garcia, Luis D; Cruz-Collazo, Ailed et al. (2015) Equol, an isoflavone metabolite, regulates cancer cell viability and protein synthesis initiation via c-Myc and eIF4G. J Biol Chem 290:6047-57|
|Castillo-Pichardo, Linette; Humphries-Bickley, Tessa; De La Parra, Columba et al. (2014) The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model. Transl Oncol 7:546-55|
|Castillo-Pichardo, Linette; Dharmawardhane, Suranganie; Rodríguez-Orengo, José F (2014) Rapid quantification of resveratrol in mouse plasma by ultra high pressure liquid chromatography (UPLC) coupled to tandem mass spectrometry. P R Health Sci J 33:151-6|
|Castillo-Pichardo, Linette; Cubano, Luis A; Dharmawardhane, Suranganie (2013) Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complement Altern Med 13:6|
|Dharmawardhane, Suranganie; Hernandez, Eliud; Vlaar, Cornelis (2013) Development of EHop-016: a small molecule inhibitor of Rac. Enzymes 33 Pt A:117-46|
|de la Parra, Columba; Otero-Franqui, Elisa; Martinez-Montemayor, Michelle et al. (2012) The soy isoflavone equol may increase cancer malignancy via up-regulation of eukaryotic protein synthesis initiation factor eIF4G. J Biol Chem 287:41640-50|
Showing the most recent 10 out of 13 publications